
    
      Patients with angiographically documented acute intracranial vertebrobasilar artery occlusion
      presenting within 24 hours of neurological symptom onset will be enrolled into this
      open-label trial. During study drug administration, angiograms will be repeated at regular
      intervals to determine degree of clot lysis.
    
  